New Hampshire § 126-Z:3 Liability of Physician;  Facility

New Hampshire Statutes

§ 126-Z:3 — Liability of Physician; Facility

New Hampshire § 126-Z:3

Title XPUBLIC HEALTH

Ch. 126-ZRIGHT TO TRY ACT

This text of New Hampshire § 126-Z:3 (Liability of Physician; Facility) is published on Counsel Stack Legal Research, covering New Hampshire primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook

N.H. Rev. Stat. Ann. § 126-Z:3 (2026).

Text

I.Notwithstanding any provision of law to the contrary, the board of medicine shall not revoke, fail to renew, or take any other action against a physician's license issued pursuant to RSA 329 based primarily on a physician's recommendation to an eligible patient regarding or prescription for or treatment with an investigational drug, biologic, or device.

II.Notwithstanding any provision of law to the contrary, the department of health and human services shall not take action against a facility licensed under RSA 151 based primarily on the institution's participation in the treatment or use of an investigational drug, biologic, or device under this chapter. [Paragraph III effective January 1, 2026.]

III.Notwithstanding any provision of law to the contrary, a manufacturer of a drug, biol

Free access — add to your briefcase to read the full text and ask questions with AI

I. Notwithstanding any provision of law to the contrary, the board of medicine shall not revoke, fail to renew, or take any other action against a physician's license issued pursuant to RSA 329 based primarily on a physician's recommendation to an eligible patient regarding or prescription for or treatment with an investigational drug, biologic, or device.
II. Notwithstanding any provision of law to the contrary, the department of health and human services shall not take action against a facility licensed under RSA 151 based primarily on the institution's participation in the treatment or use of an investigational drug, biologic, or device under this chapter.
[Paragraph III effective January 1, 2026.]
III. Notwithstanding any provision of law to the contrary, a manufacturer of a drug, biologic, or device, a pharmacist, a health care facility, a health care provider, or a person or entity involved in the care of a patient using a drug, biologic, or device is immune from suit for any harm done to a patient resulting from the drug, biologic, or device if:
(a) The person has a terminal illness as determined by the person's physician and a consulting physician;
(b) The person's physician has determined that the person has no comparable or satisfactory United States Food and Drug Administration (FDA) approved treatment options available to treat the disease or condition involved;
(c) The patient has given written informed consent for the use of the drug, biologic, or device or, if the patient is a minor or lacks the mental capacity to provide informed consent, a parent or legal guardian has given written informed consent on the patient's behalf and, if the patient is a legal adult, the consent is not contrary to the prior documented wishes of the patient;
(d) The manufacturer, pharmacist, facility, provider, or other person or entity has not engaged in willful or reckless misconduct or other bad faith conduct. "Willful or reckless misconduct" shall include, but is not limited to, any conduct intended to hasten the death of the patient; and
(e) If the drug, biologic, or device is an individualized investigational treatment, it is administered by a health care provider at an eligible facility.